Patient Invoice Payment Link
Contact Us

Advanced STI PCR Panel

Comprehensive, Rapid, and Clinically Actionable Detection

Why Molecular PCR for STI Testing?

Sexually transmitted infections are frequently polymicrobial, asymptomatic, and clinically overlapping. Traditional diagnostic methods often miss co-infections, delay treatment, or fail to identify fastidious organisms.

Our multiplex PCR STI panel delivers high-sensitivity, high-specificity detection of bacterial, viral, and protozoal pathogens in a single test — enabling earlier diagnosis, targeted therapy, and improved patient outcomes.

Sexually Transmitted Infection (STI) — Pathogen Panel

Bacteria
16 targets
Atopobium vaginae
Bac (gram-positive)
Bacterial Vaginosis-Associated Bacterium 1
Bac (gram-variable)
Bacterial Vaginosis-Associated Bacterium 2
Bac (gram-positive)
Bacterial Vaginosis-Associated Bacterium 3
Bac (gram-positive)
Chlamydia trachomatis
Bac (gram-positive)
Gardnerella vaginalis
Bac (gram-positive)
Haemophilus ducreyi
Bac (gram-positive)
Megasphaera type II
Bac (gram-positive)
Lactobacillus spp. (crispatus/reuteri/gasseri/vaginalis/jensenii)
Bac (gram-positive)
Megasphaera type I
Bac (gram-positive)
Mobiluncus curtisii
Bac (gram-positive)
Mobiluncus mulieris
Bac (gram-positive)
Mycoplasma genitalium
Bac (gram-positive)
Neisseria gonorrhoeae
Bac (gram-positive)
Treponema pallidum
Bac (gram-positive)
Ureaplasma spp. (urealyticum/parvum)
Bac (gram-positive)
Virus
1 targets
Herpes simplex virus (HSV) 1 and 2
Protozoa
1 targets
Trichomonas vaginalis
Protozoa

Broad Pathogen Coverage for Complete Clinical Insight

This panel detects a wide spectrum of clinically relevant organisms, including:

Bacterial Pathogens

  • Chlamydia trachomatis
  • Neisseria gonorrhoeae
  • Mycoplasma genitalium
  • Treponema pallidum
  • Haemophilus ducreyi
  • Ureaplasma spp.

Vaginal Microbiome & BV-Associated Organisms

  • Atopobium vaginae
  • Gardnerella vaginalis
  • BVAB 1, 2, 3
  • Megasphaera types I & II
  • Mobiluncus curtisii & mulieris
  • Lactobacillus spp. (commensal balance markers)

Viral Pathogens

  • Herpes Simplex Virus (HSV-1 & HSV-2)

Protozoal Pathogens

  • Trichomonas vaginalis

All targets confirmed from the attached panel specification

Clinical Utility — Why This Panel Matters

1. Detects Co-Infections That Drive Persistent Symptoms

  • Many patients present with multiple concurrent infections
  • PCR enables simultaneous detection, eliminating diagnostic gaps
  • Particularly valuable in:
  • Recurrent vaginitis
  • Persistent urethritis/cervicitis
  • Treatment failures

2. Improves Diagnostic Accuracy Over Traditional Methods

  • Culture and microscopy have limited sensitivity
  • PCR identifies:
  • Fastidious organisms (Mycoplasma genitalium, Ureaplasma spp.)
  • Low organism burden infections
  • *Non-culturable pathogens

3. Enables Targeted, Evidence-Based Treatment

  • Differentiates:
  • Bacterial STI vs. Vaginal dysbiosis (BV) vs. Protozoal infection
  • Supports:
  • Antibiotic stewardship
  • Reduced empiric therapy
  • More precise clinical decision-making

4. Provides Insight into Vaginal Microbiome Health

  • Detection of Lactobacillus spp. vs. BV-associated organisms helps:
  • Identify dysbiosis
  • Guide restorative therapies
  • Reduce recurrence rates

5. Rapid Turnaround = Faster Treatment

  • Results available within ~24 hours
  • Supports:
  • Same-day or next-day clinical intervention
  • Reduced transmission risk
  • Improved patient compliance

6. Enhances Care in High-Risk and Underserved Populations

  • Ideal for:
  • Women with recurrent vaginal symptoms
  • Patients with negative cultures but persistent symptoms
  • High-risk populations (multiple partners, prior STIs)
  • Prenatal and fertility evaluations

Clinical Scenarios Where This Panel Excels

Recurrent Vaginitis

Differentiates BV, STI, and mixed infections

Urethritis/Cervicitis with Negative Standard Testing

Detects Mycoplasma genitalium and Ureaplasma spp.

Lesion-Based Testing

Confirms HSV infection rapidly

Persistent Symptoms Post-Treatment

Identifies unresolved or co-infections

Key Advantages at a Glance

Supports antimicrobial stewardship

Comprehensive pathogen coverage

High sensitivity & specificity

Rapid turnaround time

Detects polymicrobial infections

Improves patient outcomes

Elevating STI Diagnosis and Patient Care

By combining broad pathogen detection, microbiome insight, and rapid molecular diagnostics, this STI PCR panel empowers providers to:

Supports antimicrobial stewardship

Deliver targeted therapy

Reduce recurrence and complications

Improve overall patient outcomes and satisfaction